Met in Urological Cancers

Met in Urological Cancers

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predicti...

Full description

Bibliographic Details
Main Authors:	Yasuyoshi Miyata, Akihiro Asai, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Yasushi Mochizuki, Hideki Sakai
Format:	Article
Language:	English
Published:	MDPI AG 2014-12-01
Series:	Cancers
Subjects:	Met prostate cancer renal cell carcinoma urothelial cancer pathological features survival target therapy
Online Access:	http://www.mdpi.com/2072-6694/6/4/2387

Similar Items

Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies
by: Lucas Nogueira, et al.
Published: (2020-11-01)

A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis
by: Yasuyoshi Miyata, et al.
Published: (2017-10-01)

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
by: Yasuyoshi Miyata, et al.
Published: (2019-05-01)

Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
by: Shoichiro Mukai, et al.
Published: (2020-04-01)

Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy
by: Pranav Sharma, et al.
Published: (2016-01-01)

Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer
by: Guang-Xi Sun, et al.
Published: (2017-01-01)

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
by: Young H. Lee, et al.
Published: (2014-11-01)

Urothelial-Type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma
by: Brian P. Adley, et al.
Published: (2006-12-01)

Metastatic Prostate Cancer to the Urethra Masquerading as Urothelial Carcinoma
by: Ibrahim Zardawi, et al.
Published: (2016-07-01)

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
by: Dai Yao, et al.
Published: (2012-05-01)

Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
by: Sun Tae Hwang, et al.
Published: (2020-03-01)

Clinicopathological impacts of c-Met overexpression in bladder cancer: evidence from 1,336 cases
by: Xu X, et al.
Published: (2019-04-01)

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
by: Brigida Anna Maiorano, et al.
Published: (2021-06-01)

Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
by: Kensuke Mitsunari, et al.
Published: (2021-01-01)

A rare case of a patient with primary urothelial carcinoma of the prostate urethra - Multidisciplinary approach
by: Antonov P., et al.
Published: (2021-09-01)

Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects
by: Yasuyoshi Miyata, et al.
Published: (2013-06-01)

Relevance of prostate cancer in patients with synchronous invasive bladder urothelial carcinoma: a monocentric retrospective analysis
by: Lucio Dell’Atti
Published: (2015-03-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)

Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study
by: Hairong He, et al.
Published: (2021-07-01)

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
by: Yasuyoshi Miyata, et al.
Published: (2020-12-01)

<sup>18</sup>F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study
by: Fabio Zattoni, et al.
Published: (2019-05-01)

Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract
by: Miyata Yasuyoshi, et al.
Published: (2012-08-01)

Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice
by: A. S. Zhabina, et al.
Published: (2021-06-01)

Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer
by: Yasuyoshi Miyata, et al.
Published: (2019-01-01)

MET and Small-Cell Lung Cancer
by: Francesco Gelsomino, et al.
Published: (2014-10-01)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
by: Bylicki O, et al.
Published: (2020-06-01)

Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer
by: Tomhiro Mastuo, et al.
Published: (2020-01-01)

c-Met and miRs in Cancer
by: Simona Giglio, et al.
Published: (2015-01-01)

Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors
by: Yıldız Y, et al.
Published: (2016-09-01)

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake
by: Tomohiro Matsuo, et al.
Published: (2021-02-01)

Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer
by: Mubarak Al-mansour, et al.
Published: (2014-01-01)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
by: Filippos Koinis, et al.
Published: (2020-01-01)

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers
by: Matteo Santoni, et al.
Published: (2019-08-01)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
by: Yasuyoshi Miyata, et al.
Published: (2018-08-01)

Advisory Council on combined immunochemotherapy for urothelial cancer
by: article Editorial
Published: (2020-11-01)

ROLE OF NEUREGULINS AND HEPATOCYTE GROWTH FACTOR IN THE DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: L. V. Spirina, et al.
Published: (2016-02-01)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
by: Federica Papaccio, et al.
Published: (2018-11-01)

Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes
by: Liangyou Gu, et al.
Published: (2020-11-01)

Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy
by: Foerster Robert, et al.
Published: (2017-09-01)